학술논문
Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma.
Document Type
Article
Author
Henckens, Sofie P G; Liu, Dajia; Gisbertz, Suzanne S; Kalff, Marianne C; Anderegg, Maarten C J; Crull, David; Daams, Freek; van Dalsen, Annette D; Dekker, Jan Willem T; van Det, Marc J; van Duijvendijk, Peter; Eshuis, Wietse J; Groenendijk, Richard P R; Haveman, Jan Willem; van Hillegersberg, Richard; Luyer, Misha D P; Olthof, Pim B; Pierie, Jean-Pierre E N; Plat, Victor D; Rosman, Camiel
Source
Subject
*PROGNOSIS
*COMBINED modality therapy
*OVERALL survival
*NEOADJUVANT chemotherapy
*ADENOCARCINOMA
*RECTAL cancer
*HEARTBURN
*
*
*
*
*
*
Language
ISSN
0007-1323
Abstract
Background: This study evaluated the association of pathological tumour response (tumour regression grade, TRG) and a novel scoring system, combining both TRG and nodal status (TRG-ypN score; TRG1-ypN0, TRG>1-ypN0, TRG1-ypN+ and TRG>1-ypN+), with recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma. Methods: This Dutch nationwide cohort study included patients treated with neoadjuvant chemoradiotherapy followed by oesophagectomy for distal oesophageal or gastro-oesophageal junctional adenocarcinoma between 2007 and 2016. The primary endpoint was the association of Mandard score and TRG-ypN score with recurrence patterns (rate, location, and time to recurrence). The secondary endpoint was overall survival. Results: Among 2746 inclusions, recurrence rates increased with higher Mandard scores (TRG1 30.6%, TRG2 44.9%, TRG3 52.9%, TRG4 61.4%, TRG5 58.2%; P < 0.001). Among patients with recurrent disease, the distribution (locoregional versus distant) was the same for the different TRG groups. Patients with TRG1 developed more brain recurrences (17.7 versus 9.8%; P = 0.001) and had a longer mean overall survival (44 versus 35 months; P < 0.001) than those with TRG>1. The TRG>1-ypN+ group had the highest recurrence rate (64.9%) and worst overall survival (mean 27 months). Compared with the TRG>1-ypN0 group, patients with TRG1-ypN+ had a higher risk of recurrence (51.9 versus 39.6%; P < 0.001) and worse mean overall survival (33 versus 41 months; P < 0.001). Conclusion: Improved tumour response to neoadjuvant therapy was associated with lower recurrence rates and higher overall survival rates. Among patients with recurrent disease, TRG1 was associated with a higher incidence of brain recurrence than TRG>1. Residual nodal disease influenced prognosis more negatively than residual disease at the primary tumour site. In this Dutch nationwide cohort study, improved tumour response to neoadjuvant therapy was associated with a lower recurrence rate and higher overall survival rate. Among patients with recurrent disease, tumour regression grade (TRG) 1 was associated with a higher incidence of brain recurrences than TRG greater than 1. Residual nodal disease influenced prognosis more negatively than residual disease at the primary tumour site. [ABSTRACT FROM AUTHOR]